Biomarker Panel UTI Detection Reducing Misdiagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting urinary tract infections (UTIs) are often delayed and prone to misdiagnosis, leading to inappropriate antibiotic use and antibiotic resistance, as traditional urine culture results take two days and clinical criteria are not always accurate.
Innovation Solution
A method involving the detection of specific biomarkers such as MMP8, HNE, Cystatin C, MMP9, IL-8, IL-6, IL-1b, fibrinogen, RBP4, NGAL, Desmosine, MPO, and CRP in urine samples, with threshold comparisons to rapidly and accurately diagnose and monitor UTIs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If urine culture is used as the gold standard test for UTI, then diagnostic accuracy is improved, but time delay increases (2 days waiting period)
Solution Approach 1:
The patent performs preliminary detection of UTI using biomarker panels (such as nitrite, leukocyte esterase, lactoferrin, and other inflammatory markers) before the gold standard culture results are available. This allows clinicians to make early diagnostic decisions and initiate appropriate treatment without waiting 2 days for culture results, while still maintaining high diagnostic accuracy through multi-marker analysis.
2Loss of time
If clinical criteria alone are used for UTI diagnosis, then time loss is reduced (immediate diagnosis), but measurement precision deteriorates (one third misdiagnosis rate)
Solution Approach 1:
The patent combines multiple clinical criteria with a panel of biomarker detections (including nitrite, leukocyte esterase, lactoferrin, and additional inflammatory markers) to create a comprehensive diagnostic system. This merging of clinical assessment with multi-marker biochemical analysis maintains rapid point-of-care diagnosis while significantly improving diagnostic accuracy beyond clinical criteria alone, reducing the one-third misdiagnosis rate through objective multi-parameter measurement.
3Productivity
If empirical antibiotic treatment is prescribed based on clinical criteria, then productivity is improved (immediate treatment), but harmful factors increase (antibiotic resistance)
Solution Approach 1:
The patent implements a feedback mechanism where the results of rapid biomarker panel detection directly inform antibiotic prescribing decisions. By providing immediate, accurate diagnostic information about the presence and severity of UTI, the system enables clinicians to prescribe antibiotics only when truly indicated, avoiding unnecessary empirical treatment. This feedback loop reduces inappropriate antibiotic use and helps combat antibiotic resistance while maintaining efficient treatment of confirmed cases.
Data Source
AI summary
Method for detecting a urinary tract infection (UTI) in a subject comprising determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject. The determined levels may then be compared with a threshold level, wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection. Methods for monitoring a UTI and monitoring treatment of a UTI are also provided as are companion systems or test kits.